Management

The leadership team at BBS includes individuals with over 25 years experience in drug development for large, international pharmaceutical companies and the practice of oncology and radiology for cancer patients at some of the world’s most prestigious hospitals.

Leveraging the experience of its leadership, BBS sets the bar at the highest international standards for scientific achievement and executes to these standards.

Eszter Prépost M.D.

Head of Business & CEO

After graduating at the Medical University of Pécs (Hungary) Eszter has started as a Clinical Research Associate at Sanofi-Aventis.

After gaining knowledge on various therapeutic areas she moved on to set up the local affiliate of an international Contract Research Organization (Averion International) as a general manager at the same time leading the local team, providing project management as well as client liaison and business development services.

She gained further insight on clinical research, particularly on cross-functional and international collaborations at a multinational pharma company (Merck Sharp & Dohme) as an associate director where she was exposed to tasks on a regional scale.

Krisztina Kerekes, Ph.D.

Head of Laboratory

Dr. Krisztina Kerekes graduated in biology and received her Ph.D. from Eötvös Loránd University, Budapest.
She has worked at BBS Nanotechnology since 2012. Prior to it, she was at the Department of Immunology of Eötvös Loránd University (Budapest) where she was researching the innate immun system and participated in teaching of Practice of Immunology. Dr. Kerekes is coauthor of 17 peer reviewed scientific papers and 2 granted US Patents
She has great experience in most of the cellbiological works, in different biological tests and their evaluations. She coordinates the laboratory work of BBS and keeps contact with external providers.

Sándor Farkas M.D.

Chief Scientific Officer

Sándor Farkas M.D. Chief Scientific Officer, is a nonclinical pharmacologist and drug developing expert, Medical Doctor, with 34 years of experience in the Pharma Industry.

Particular areas of expertise include all phases of early drug development from target identification to non-clinical support of clinical development.

Specialty expertise include electrophysiology, safety pharmacology, integrated evaluation of efficacy, safety and ADME data; medical writing. Author of 37 scientific publications and co-inventor of 21 patent applications involving 5 drug candidates reaching clinical development.

He was also involved in early development of a new drug (Cariprazine) that was approved recently by FDA.

Board of Directors

The BBS Board of Directors comprises the founder as well as representatives of Primus Capital. The Board of Directors combines 30+ years of management with investments experience in the European biopharma markets.

István Alpek

Director, Primus Capital

István Alpek is co-founder of Primus III, bringing extensive experience in finance as well as venture capital. Prior to joining Primus, István held posts such as investment director at 3TS Capital Partners, CFO and COO of VC-funded Euronet, which went public with a NASDAQ IPO, CFO and COO of CV-Online, founder and managing director of investment advisory firm AD Capital, finance head at DuPont’s Hungarian subsidiary and Digital Equipment Hungary and as senior consultant at PricewaterhouseCoopers in Budapest.

He holds an MBA from the University of Pittsburgh and a BA from the College of Foreign Trade in Budapest. He is a chartered investment advisor in Hungary and member of the Hungarian Venture Capital Association (HVCA)’s Education Committee. Married with two children, István is fluent in English in addition to his native Hungarian.(Director, Primus Capital) is co-founder of Primus III, bringing extensive experience in finance as well as venture capital. Prior to joining Primus, István held posts such as investment director at 3TS Capital Partners, CFO and COO of VC-funded Euronet, which went public with a NASDAQ IPO, CFO and COO of CV-Online, founder and managing director of investment advisory firm AD Capital, finance head at DuPont’s Hungarian subsidiary and Digital Equipment Hungary and as senior consultant at PricewaterhouseCoopers in Budapest.

He holds an MBA from the University of Pittsburgh and a BA from the College of Foreign Trade in Budapest. He is a chartered investment advisor in Hungary and member of the Hungarian Venture Capital Association (HVCA)’s Education Committee. Married with two children, István is fluent in English in addition to his native Hungarian.

János Borbély, Ph.D.

Founder

Dr. Borbély founded BBS Nanotechnology in 2005. Prior to BBS Nanotechnology, Dr. Borbély was at the University of Debrecen where he taught Environmental Science and Colloid Chemistry, and led a research program aimed at developing a novel nanosystems. Dr. Borbély is an established expert in Biomacromolecular Science and has been involved in the design and development of Biopolymer-based Nanosystems for most of his 30+ year career. Dr. Borbély is honored to have served as Deputy State Secretary for the Environment in the Hungarian Government from 1998 to 2001, an appointment that was based on his expertise in Environmental Science. His experience in the government motivated Dr. Borbély to use his knowledge of chemistry to solve the problem of the release of volatile organic compounds into the environment which was until that time inherent in the chemistry of nanosystems. In addition to drug and contrast agent delivery nanosystems, Dr. Borbély has invented and designed biopolymer based nanosystems for water purification including combined membrane-nano filtration. Dr. Borbély is coauthor of more than one hundred peer reviewed scientific papers and five granted US Patents. Dr. Borbely received his M.Sc. and his Ph.D. from the University of Debrecen, and was a Visiting Professor at the University of Queensland and Fulbright fellow at the University of Massachusetts at Amherst.

Gábor Heltovics

Member of the Board

Gábor Heltovics holds Master’s degrees in Biology (1995), Chemistry (1995), and Business Administration (MBA, 2003). He is the CEO of Druggability Technologies Holdings Ltd, a technology based specialty pharmaceutical company. He is a seasoned entrepreneurial senior executive with extensive R&D and general management experience in this field in the US, UK, and EU. He has a successful track record of innovation management and technology platform development in major multinational corporations such as Procter & Gamble and Coca-Cola, as well as SME Bio-pharmaceutical companies such as SOLVO Biotechnology.

András Szombati

partner & investment director

András Szombati, co-founder of Primus III, brings 10 years of venture capital experience to Primus, in biotech, health care and services, among others, including four successful exits with an average IRR of over 30 percent. András was previously managing director of venture capital fund Eclipse Ltd., which is affiliated with Concorde Securities Ltd., Hungary’s largest independent investment banking services provider, and managing director and co-founder of the First Hungarian Film Fund. András gained experience in structured lending and corporate finance at ING Barings in Budapest and South Africa. He is a member of the Hungarian Biotechnology Association and the Hungarian Venture Capital Association, and holds an MBA from the Budapest University of Economics (today Corvinus University), where he is a guest lecturer, and a degree from Montgomery College in Washington, D.C. Married with three children, András is fluent in English in addition to his native Hungarian.